INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in LifeMD, Inc. of Class Action Lawsuit and Upcoming Deadlines - LFMD

Group 1 - A class action lawsuit has been filed against LifeMD, Inc. for alleged securities fraud and unlawful business practices [2][4] - Investors have until October 27, 2025, to request appointment as Lead Plaintiff if they purchased LifeMD securities during the Class Period [2] - Following the announcement of revised full-year 2025 guidance due to challenges in the Rex MD business, LifeMD's stock price dropped by $5.31, or 44.85%, closing at $6.53 per share [4] Group 2 - LifeMD's CFO stated that the company anticipates strong year-over-year growth in revenue and adjusted EBITDA despite temporary challenges [4] - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud [5]